Tag - Pyramid Biosciences

08 Jul

FDA Grants Orphan Drug Designation to PBI-200 for NTRK Fusion–Positive Solid Tumors

The FDA has granted an orphan drug designation to PBI-200 for the treatment of patients with NTRK fusion–positive solid tumors, including primary and metastatic brain tumors. PBI-200, which is an oral, highly potent and selective inhibitor of TRK kinase, was designed by Pyramid Biosciences to overcome a wide range of on-target resistance mutations that have been observed with first-generation TRK inhibitors. “Oncogenic NTRK gene fusions are found in a broad range of cancers. Orphan designation for drugs in development […]

Portfolio News Read more...
13 Apr

Pyramid Biosciences Announces TIME Trial™ Program Collaboration with Tempus for Patients with NTRK Fusion Solid Tumors

Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a range of serious diseases, today announced a collaboration with Tempus, a leader in artificial intelligence and precision medicine, to strengthen and amplify identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial of Pyramid’s lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor (PBI-200-101). Read more >>

Portfolio News Read more...
11 Jan

Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief Executive Officer

Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the appointment of Brian Lestini, MD, PhD as Chief Executive Officer. Dr. Lestini joined Pyramid Biosciences in March 2021 as the Chief Medical Officer, overseeing the advancement and expansion of the company’s clinical pipeline of novel targeted medicines. Pyramid Biosciences’ lead program, PBI-200, currently in Phase 1 clinical trials, is an orally-active, CNS penetrant TRK inhibitor targeting a […]

Portfolio News Read more...
02 Dec

Pyramid Biosciences’ $864 Million Licensing Deal

Clinical-stage biotechnology company Pyramid Biosciences, Inc. announced the development of a global licensing deal for two cancer therapies worth up to $846 million. The licensing agreement with South Korea-based biotechnology company Voronoi, Inc. will bring a novel monopolar spindle1 (MPS1) called VRN-08 and second undisclosed asset into Pyramid Bioscience’s portfolio of precision oncology therapeutics. MPS1 is involved in core-of-tumor cell division. The novel inhibitor VRN-08 selectively blocks this process, ultimately leading to tumor cell death. Founded in 2015, Waltham, […]

Portfolio News Read more...
17 Nov

Pyramid Biosciences Expands Precision Oncology Pipeline

Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the global licensing of the novel monopolar spindle1 (MPS1) called VRN-08 and a second undisclosed asset from Voronoi Inc., a South Korea-based biotechnology company the develops novel kinase inhibitors and target protein degraders. The milestone-based deal is worth up $846 million dollars (USD). Read more >>

Portfolio News Read more...
28 Oct

Pyramid Biosciences Announces Initial Closing of Series B Financing for Clinical Program Acceleration

Pyramid Biosciences, Inc., a clinical stage, biotechnology company developing a portfolio of precision therapies targeting a wide range of molecularly-defined diseases, today announced the initial close of its Series B financing. The financing will support the clinical development of multiple programs focused on novel tropomyosin receptor kinase (TRK) modulators. The funding round was led by Oracle Investment Management, Inc., along with support from Adage Capital Management, Averill Master Fund, Ltd., J.W. Childs Associates L.P. as well as several other […]

Portfolio News Read more...
15 Apr

Pyramid Biosciences Announces Leadership Team Expansion

Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced two new appointments to the leadership team.“We are looking forward to Dr. Lestini’s leadership of our clinical programs during this important growth stage of our company.” Brian Lestini, MD, PhD, has joined the company as Chief Medical Officer, where he will oversee the advancement and expansion of the Company’s clinical pipeline. Read more >>

Portfolio News Read more...
18 Dec

Pyramid Biosciences Announces Exclusive Global License of AstraZeneca TRK Program for Dermatology and Inflammatory Diseases

Pyramid Biosciences, Inc. (www.pyramidbio.com), a Boston-based biotechnology company developing new therapies focused on the modulation of cell surface receptors today announced it has entered into an exclusive, worldwide licensing agreement with AstraZeneca PLC for the development and commercialization rights to a novel Tropomyosin receptor kinase (TRK) modulator, PBI-100. Read more >>

Portfolio News Read more...